ANGIOTENSIN THERAPEUTICS, INC.

Biotech · Private

Bioengineered soluble ACE2 (AGT001) therapeutic protein that degrades angiotensin II to treat scleroderma kidney disease

Grants
$910K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Lung delivery of novel ACE2 variants for COVID-19$299,842
Federal grantDepartment of Health and Human Services · Phase I · AGT001 for Delayed Graft Function in Kidney Transplantation$314,355
Federal grantDepartment of Health and Human Services · Phase I · AGT001 for Scleroderma Kidney$295,744
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1932Akeso Therapeutics Inc——
1933XEME Biopharma, Inc.—$10M
1934Boston Mountain Biotech, LLC—$8.4M
1935ANGIOTENSIN THERAPEUTICS, INC.——
1936CELLARCUS TECHNOLOGIES, LLC——
1937DeepSpace Storage Systems Inc.—$1.3M
1938Centrexion Therapeutics Corp—$189M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.